The Latest Cardiac and Vascular News
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) — E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced that it is set to initiate a Phase 2 clinical trial of MANP for the treatment of Resistant Hypertension (BOLD-HTN) supported by a recent round of financing.
Program reduced all-cause 30-day readmissions for CHF patients by 50 percent using a combination of AI-powered technology and remote human care teams. SOUTHBRIDGE, Mass., Oct. 8, 2024 /PRNewswire/ — UMass Memorial Health – Harrington (“Harrington”), the health and wellness provider for…
MINNEAPOLIS, Oct. 8, 2024 /PRNewswire/ — 4C Medical Technologies, Inc. (“4C Medical”), a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, has commenced enrollment in the ATLAS (A Transseptal Left Atrial System for Treatment of…
MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced the completion of enrollment in the “Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)” trial. “For decades, managing fluid removal in patients with […]
Caesarea, Israel – Oct. 3, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions through cutting-edge technology, announces the installation of its SpotLight™ Duo cardiac CT scanner at Lehigh Valley Health Network’s (LVHN) cardiac diagnostic center in Gilbertsville, Pennsylvania. This installation through Lehigh Valley Imaging makes the SpotLight Duo […]
Patients identified with reduced ejection fraction using Eko Health AI were twice as likely to experience heart attacks, heart failure, hospitalization, and all-cause mortality over two years. SAN FRANCISCO, Oct. 2, 2024 /PRNewswire/ — Eko Health, a pioneer in applying artificial…
WASHINGTON, Oct. 1, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) announced today during their Annual Scientific Meeting the launch of a new journal, JCF-Intersections (JCF-I), in partnership with Elsevier. This new journal will join the JCF Family of Journals, led by…
Study will assess the Company’s Next-Generation device under Intracardiac Echocardiography (ICE) imaging for Left Atrial Appendage Occlusion (LAAO) procedures. NASHUA, N.H., Oct. 1, 2024 /PRNewswire/ — Conformal Medical, Inc. today announced the initiation of the GLACE Study. This…
REHOVOT, Israel–(BUSINESS WIRE)–Pi-Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market clearance for ShortCut™ – the world’s first dedicated leaflet modification device, enabling valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures […]
– Results from the placebo-controlled study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) were presented in a Late Breaking Clinical Trial Plenary Session at the HFSA Annual Scientific Meeting 2024 – – Data showed patients treated with HU6…
